TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29064409

Group type: COMPARATOR
Intervention: Control diet (10:1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: α‐linolenic acid (ALA) diet (2:1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) diet (10:1 plus supplement)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination diet (2:1 + S)
Number of subjects: 24
Study: 26216528

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endogenous molecules (metabolites such as tryptophan, alanine, arachidonic acid, 2-hydroxybutyric acid, cholesterol, and isoleucine)
Number of subjects: 48
Study: 23541216

Group type: EXPERIMENTAL
Intervention: Experimental text (lower Flesch-Kincaid reading grade level of 7.4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control text (higher Flesch-Kincaid reading grade level of 9.6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental text (adjusted for age, education, and health literacy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental text (limited to persons with college degrees)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental text (limited to persons with no self-reported health literacy problems)
Number of subjects: 60
Study: 21502571

Group type: EXPERIMENTAL
Intervention: Atopaxar 50 mg daily
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Atopaxar 100 mg daily
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Atopaxar 200 mg daily
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Atopaxar (all regimens)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Atopaxar
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Atopaxar (higher doses)
Number of subjects: 720
Study: 19662793

Group type: EXPERIMENTAL
Intervention: 5% glucose solution (1000 mL) one day before surgery
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Postoperative non‐glucose crystalloid solutions
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Postoperative use of insulin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Postoperative replacement with cristalloids and insulin
Number of subjects: 208
Study: 16445447

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM) solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo intracamerally
Number of subjects: 80
Study: 15538125

Group type: COMPARATOR
Intervention: Fluvoxamine plus placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus risperidone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluvoxamine only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Augmentation strategy with risperidone
Number of subjects: 30
Study: 11273218

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 3 months or more
Number of subjects: 551

Group type: COMPARATOR
Intervention: Formula feeding (never breastfed)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding
Number of subjects: 551

Group type: COMPARATOR
Intervention: Other breastfeeding (mixed or formula)
Number of subjects: 551
Study: 9634163

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study: 8176922

Group type: EXPERIMENTAL
Intervention: Three courses of cisplatinum containing combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less than three courses of chemotherapy
Number of subjects: 0
Study: 3204636

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-focus (dispositional self-consciousness)
Number of subjects: 0
Study: 31607388

Group type: EXPERIMENTAL
Intervention: TOFR >0.95
Number of subjects: 3150

Group type: COMPARATOR
Intervention: TOFR >0.9
Number of subjects: 3150
Study: 30106253

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28971615

Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26093872

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1996
Study: 23139058

Group type: EXPERIMENTAL
Intervention: Face-to-face (FtF) exercise intervention
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Telephone (Tel) exercise intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 194
Study: 22078184

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of MPA 25 mg + E(2)-Cyp 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular administration of MPA 25 mg + E(2)-Cyp 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both SC and IM administration
Number of subjects: 30
Study: 18077124

Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy throughout pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (babies conceived off methadone)
Number of subjects: 0
Study: 16365743

Group type: EXPERIMENTAL
Intervention: Cisplatin 12.5 mg/m(2) plus radiation 36 Gy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy
Number of subjects: 85
Study: 14626750

Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) program
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional Reduced-Calorie Diet (RCD)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both MR and RCD programs
Number of subjects: 95
Study: 11105938

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg per hour)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9048349

Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal
Number of subjects: 84

Group type: COMPARATOR
Intervention: Prednisone continuation
Number of subjects: 84
Study: 8815669

Group type: EXPERIMENTAL
Intervention: Microwave sterilization of catheters (800 W for over 6 minutes after washing with water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (catheters thoroughly washed before microwave treatment)
Number of subjects: 30
Study: 2533878

Group type: EXPERIMENTAL
Intervention: 4% erythromycin and zinc combination (Zineryt)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 2% erythromycin (Eryderm)
Number of subjects: 122
Study: 335571

Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopheryl nicotinate (600 mg, 6 capsules a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study: 30040242

Group type: EXPERIMENTAL
Intervention: Nonanimal chondroitin sulfate (800 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animal-derived chondroitin sulfate
Number of subjects: 0
Study: 28320635

Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (400 million cells)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (1200 million cells)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Multipotent adult progenitor cells (combined groups 2 and 3)
Number of subjects: 129
Study: 26075918

Group type: EXPERIMENTAL
Intervention: Open/free-spirited dater profile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional/uptight dater profile
Number of subjects: 0
Study: 25141240

Group type: EXPERIMENTAL
Intervention: Intact ER OC/APAP 30/1300 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intact IR OC/APAP 30/1300 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intact ER OC/APAP 15/650 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Crushed ER OC/APAP 30/1300 mg
Number of subjects: 55
Study: 22270557

Group type: EXPERIMENTAL
Intervention: Past users of coffee, tea, or alcoholic beverages
Number of subjects: 664

Group type: COMPARATOR
Intervention: Current users of coffee, tea, or alcoholic beverages
Number of subjects: 664

Group type: COMPARATOR
Intervention: Never users of coffee, tea, or alcoholic beverages
Number of subjects: 664
Study: 20659607

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Midazolam 0.2 mg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Number of subjects: 32
Study: 17987388

Group type: EXPERIMENTAL
Intervention: Self-administered with telephone support (SA)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Group-administered (PA)
Number of subjects: 331
Study: 15834297

Group type: EXPERIMENTAL
Intervention: Lacidipine (n = 96)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Atenolol (n = 78)
Number of subjects: 278
Study: 12376504

Group type: EXPERIMENTAL
Intervention: CAG repeats <22
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Decrease in CAG length
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: GGC repeats
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: GGC repeats <=17
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CAG <22 and GGC <=17
Number of subjects: 600

Group type: COMPARATOR
Intervention: CAG and GGC repeats
Number of subjects: 600
Study: 9894041

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional physical education class (PE)
Number of subjects: 0
Study: 8699839

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 37
Study: 1760713

Group type: EXPERIMENTAL
Intervention: MCT/LCT solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LCT solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LCT-containing solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCT-containing solutions
Number of subjects: 0
Study: 6291361

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 6.25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 12.5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 12.5 to 50 mg every 8 hours long-term
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril (CPT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prazosin 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 25 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 18
Study: 30299198

Group type: EXPERIMENTAL
Intervention: Resistance Training + Epicatechin (RT+EP)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epicatechin (EP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 62
Study: 28748386

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 25324431

Group type: EXPERIMENTAL
Intervention: Intervention group (in-depth counseling from baseline to 3 months)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (standard advice on negative health outcomes)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (regardless of assignment)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Parents who reported smoking fewer cigarettes
Number of subjects: 119
Study: 22898037

Group type: EXPERIMENTAL
Intervention: Cetuximab plus bevacizumab (15 mg/kg on day 1 given intravenously every 21 days until disease progression)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cetuximab plus bevacizumab
Number of subjects: 46
Study: 21471258

Group type: EXPERIMENTAL
Intervention: Bupivacaine group (20 mL bupivacaine 0.25% and 0.5 mL adrenaline 1/200,000 each side)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (20.5 mL normal saline each side)
Number of subjects: 70
Study: 19398921

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Number of subjects: 333

Group type: COMPARATOR
Intervention: tenofovir/emtricitabine
Number of subjects: 333
Study: 16925535

Group type: EXPERIMENTAL
Intervention: Leg massage prior to heel stick
Number of subjects: 23

Group type: COMPARATOR
Intervention: No massage prior to heel stick
Number of subjects: 23
Study: 15272109

Group type: EXPERIMENTAL
Intervention: Essential oil of lavender
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Essential oil of rosemary
Number of subjects: 26

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 26
Study: 11158752

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 480 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (all doses)
Number of subjects: 0
Study: 1335650

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (SmithKline Beecham Biologicals)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 260
Study: 6383220

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study: 30513024

Group type: EXPERIMENTAL
Intervention: TargetMatch (TM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: FirstFit (FF)
Number of subjects: 10
Study: 29397215

Group type: EXPERIMENTAL
Intervention: Indirect pulp capping (IPC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Miniature pulpotomy (MP)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Full pulpotomy (FP)
Number of subjects: 302
Study: 27109264

Group type: EXPERIMENTAL
Intervention: Taurine (6 g)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (6 g dextrose)
Number of subjects: 17
Study: 25509728

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 22313205

Group type: EXPERIMENTAL
Intervention: 3D electromagnetic navigation system
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard EVAR procedure (Control)
Number of subjects: 17
Study: 20659194

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18327081

Group type: EXPERIMENTAL
Intervention: Low Na-high K diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: High Na-low K diet
Number of subjects: 40
Study: 15943592

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (30 microg/m(2) body surface area/24 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (as a placebo)
Number of subjects: 16
Study: 12861239

Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Muscle Relaxation Therapy (APRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (quietly sitting for the same amount of time)
Number of subjects: 20
Study: 10774661

Group type: EXPERIMENTAL
Intervention: SB MMR vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Merck MMR vaccine
Number of subjects: 700
Study: 8683240

Group type: EXPERIMENTAL
Intervention: Tamoxifen (160 mg orally daily for 7 days before chemotherapy and 40 mg orally daily throughout the treatment cycle)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo (given with the same chemotherapy regimen)
Number of subjects: 199
Study: 1929686

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.3 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.625 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3881155

Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture without parenteral antibiotics (64 cases)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional treatment with incision, drainage and dressings (73 cases)
Number of subjects: 137
Study: 29981863

Group type: EXPERIMENTAL
Intervention: Intermittent DOAC use guided by continuous remote AF monitoring via dual-chamber pacemakers or implantable cardioverter-defibrillators (ICDs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (chronic DOAC administration)
Number of subjects: 48
Study: 27625094

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Long-term follow-up (LTFU)
Number of subjects: 58
Study: 24996988

Group type: EXPERIMENTAL
Intervention: Continuous morphine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (placebo)
Number of subjects: 0
Study: 22145978

Group type: EXPERIMENTAL
Intervention: Conventional SLA implants
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemically modified SLA (modSLA) implants
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both implant types
Number of subjects: 24
Study: 21565967

Group type: EXPERIMENTAL
Intervention: HI‐NPPV (mean inspiratory positive airway pressure 29 ± 4 mbar)
Number of subjects: 17

Group type: COMPARATOR
Intervention: LI‐NPPV (mean inspiratory positive airway pressure 14 mbar)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HI‐NPPV
Number of subjects: 17

Group type: COMPARATOR
Intervention: LI‐NPPV
Number of subjects: 17
Study: 18461212

Group type: EXPERIMENTAL
Intervention: 12-week exercise training programme (2 sessions per week of 45 to 60 minutes of circuit-based resistance training and aerobic exercises at 65% to 85% HRmax)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (typical 2 sessions of 40-minute physical education per week)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 12-week exercise training programme
Number of subjects: 24
Study: 16582851

Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 131

Group type: COMPARATOR
Intervention: autologous bone graft (Control)
Number of subjects: 131
Study: 12707465

Group type: EXPERIMENTAL
Intervention: Continuous therapy (3-5 mg/kg/day initially, then 0.5-3 mg/kg/day after remission)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intermittent therapy (3-5 mg/kg/day initially, then tapered off after remission)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 31
Study: 10784478

Group type: EXPERIMENTAL
Intervention: Divalproex treatment for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Divalproex treatment for 6 weeks (in subjects who completed both phases)
Number of subjects: 20
Study: 8982753

Group type: EXPERIMENTAL
Intervention: Oestradiol patch (100 micrograms/day for 6 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oestradiol patch
Number of subjects: 64
Study: 1290019

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN-gamma)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 6150945

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg nadolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 mg propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30144016

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30203757

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure plus high-dose ambroxol
Number of subjects: 200
Study: 26263283

Group type: EXPERIMENTAL
Intervention: 0.1 mg/hour nitroglycerin patch applied daily, escalating to 0.2, 0.4, or 0.6 mg/hour as tolerated
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Discontinuation of nitroglycerin
Number of subjects: 19
Study: 24756122

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel bandage contact lenses (BCLs)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no BCLs)
Number of subjects: 39
Study: 22309675

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 40
Study: 20418533

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Remifentanil-sevoflurane (Group R)
Number of subjects: 78
Study: 17401735

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual tasking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single task condition
Number of subjects: 0
Study: 16250191

Group type: EXPERIMENTAL
Intervention: Intensified transition concept (therapeutic weekend care, bedside teaching, structured information for relatives)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intensified transition concept
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard transition
Number of subjects: 62
Study: 12151907

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 116
Study: 10225643

Group type: EXPERIMENTAL
Intervention: Hot pack rewarming
Number of subjects: 134

Group type: COMPARATOR
Intervention: Routine care only (passive or no warming)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Passive warming
Number of subjects: 134

Group type: COMPARATOR
Intervention: Reflective blankets
Number of subjects: 134

Group type: COMPARATOR
Intervention: Warmed IV fluids
Number of subjects: 134

Group type: COMPARATOR
Intervention: Warmed IV fluid plus reflective blanket
Number of subjects: 134
Study: 7600653

Group type: EXPERIMENTAL
Intervention: Carvedilol (up to 25 mg BID)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 2194642

Group type: COMPARATOR
Intervention: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) without Dexamethasone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) with Dexamethasone (0.5 mg/kg)
Number of subjects: 37